Herein is reported an immunoassay for quantifying the amount of anti-drug antibody, which anti-drug antibody can specifically bind to a drug antibody, which drug antibody can specifically bind to a therapeutic target, in a serum or plasma sample comprising the steps of a) incubating the serum or plasma sample at a pH value that is about the pI value of the target, and optionally removing formed precipitate after the incubation, b) incubating the serum or plasma sample obtained in step a) at a pH value of about 2, and optionally centrifuging the incubated sample to remove formed precipitate, c) adjusting the pH value to about 7.4, adding capture antibody conjugated to a first member of a binding pair and tracer antibody conjugated to a detectable label to the serum or plasma sample obtained in step b) and incubating the mixture to form a capture antibody-anti-drug antibody-tracer antibody-complex, d) quantifying the complex formed in step c) and thereby quantifying the amount of anti-drug antibody in the serum or plasma sample.

An interstitial fluid glucose measuring device, system and method, the device including first and second cavities, both configured to be in fluid communication with interstitial fluid outside the cavities, the first and second pressure sensors being configured to sense the pressure in the first and second cavities, respectively. The first cavity includes an active solution and is defined in part by a first glucose porous membrane interfacing on one side of the interior of the first cavity and on the other side configured to interface with the interstitial body fluid. The active solution includes a lectin and a polysaccharide.

The present invention relates to methods for the identification of compounds in carbohydrate mixture compositions as well as the determination of carbohydrate mixture composition patterns, based on e.g. orthogonal cross determining migration time (indices) using capillary gel electrophoresis-laser induced fluorescence and identifying said carbohydrate components based on comparing said migration time (indices) with standard migration time (indices) from a database which data are preferably also orthogonal cross determined. In a further aspect, the present invention relates to a method for carbohydrate mixture composition pattern profiling, like glycosylation pattern profiling using capillary gel electrophoresis-laser induced fluorescence (CGE-LIF). In another aspect, the present invention refers to a system for an automated determination and/or identification of carbohydrates and/or carbohydrate mixture composition patterns (e.g.: glycosylation patterns). Finally, the present invention relates to a database containing e.g. orthogonal cross normalized migration times and/or migration time indices of carbohydrates.

Provided herein are methods of diagnosing or monitoring the treatment of mucopolysaccharidosis (MPS) I or a disorder associated with MPS I.

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

The present disclosure relates to methods of using plasma and serum (P/S) glycomics based on glycan linkage analysis that captures unique glycan features such as 2-6 sialylation, 1-6 branching, and core fucosylation as single analytical signals to evaluate the behavior of P/S glycans in all stages of lung cancer and across various stages of bladder, prostate, ovarian, and pancreatic cancer.

The present invention relates to a probe for detecting bacteria using a peptidoglycan-binding protein, and a method for preparing the same. Also, the present invention relates to a method for detecting bacteria using the probe. The probe for detecting bacteria according to the present invention can specifically detect bacteria. That is, the probe according to the present invention can clearly distinguish between yeast and bacteria and can detect both Gram-negative and Gram-positive bacteria, and thus is expected to be usable in various fields as a universal probe for detecting bacteria. Further, use of the probe allows bacteria to be detected by identifying only fluorescence development without an additional enzymatic treatment, thereby enabling a simple and quick bacterial detection. In particular, the probe is expected to be effectively usable in the food industry where quick bacterial detection is required.

An enzymatic extraction agent, as well as methods, compositions and kits for detecting Group A streptococcus in a biological sample, which involve the enzymatic agent, are described.

A method for preparing an analytical sample for analysis of a glycan contained in a sample includes: performing an amidation reaction that amidates a lactone structure included in the glycan through contacting the sample with a reaction solution that is basic; adding an acidic solution to the reaction solution after the reaction solution is subjected to the amidation reaction; and purifying the sample contained in the reaction solution after the acidic solution is added to the reaction solution by using a carrier for hydrophilic interaction chromatography.

Disclosed herein is an immunoassay method for detecting the detection target antigen in an analyte through extraction with an extraction agent. The method is characterized in that the detection is performed in the presence of a cyclic oligosaccharide. The method is also characterized in the use of an immunochromatography kit for detecting gram-positive bacteria in an analyte, and that is configured from an analyte dilution solution, a sample dropping part, an antigen extracting part, a labeling substance retaining part, an immunochromatography medium having a detection part, and an absorption part, and in which an organic acid is retained in the antigen extracting part. The immunochromatography kit contains a cyclic oligosaccharide and a nitrite compound by containing at least one of a cyclic oligosaccharide, a nitrite compound, and a mixture thereof in the analyte dilution solution and/or the sample dropping part.